AccessPak for HIV PEP Expanded with Viracept Interactions
There are 674 drugs known to interact with AccessPak for HIV PEP Expanded with Viracept (emtricitabine/nelfinavir/tenofovir), along with 11 disease interactions, and 1 alcohol/food interaction. Of the total drug interactions, 333 are major, 317 are moderate, and 24 are minor.
- View all 674 medications that may interact with AccessPak for HIV PEP Expanded with Viracept
- View AccessPak for HIV PEP Expanded with Viracept alcohol/food interactions (1)
- View AccessPak for HIV PEP Expanded with Viracept disease interactions (11)
Most frequently checked interactions
View interaction reports for AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir) and the medicines listed below.
- Advate (antihemophilic factor)
- Gammagard S/D (immune globulin intravenous)
- Keveyis (dichlorphenamide)
- Koate-HP (antihemophilic factor)
- Recombivax HB Dialysis Formulation (hepatitis b adult vaccine)
AccessPak for HIV PEP Expanded with Viracept alcohol/food interactions
There is 1 alcohol/food interaction with AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir).
AccessPak for HIV PEP Expanded with Viracept disease interactions
There are 11 disease interactions with AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir) which include:
- hepatitis B
- hepatotoxicity
- hemodialysis
- renal dysfunction
- liver disease
- PKU
- hemophilia
- hyperglycemia
- bone toxicity
- liver disease
- renal dysfunction
Report options
More about AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir)
- AccessPak for HIV PEP Expanded with Viracept consumer information
- Compare alternatives
- Side effects
- Drug class: antiviral combinations
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
